{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:35:02Z","timestamp":1783596902920,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.jim.2004.03.012","type":"journal-article","created":{"date-parts":[[2004,5,14]],"date-time":"2004-05-14T10:36:02Z","timestamp":1084530962000},"page":"97-109","source":"Crossref","is-referenced-by-count":45,"title":["Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas"],"prefix":"10.1016","volume":"289","author":[{"given":"Paul V","family":"Beum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2004.03.012_BIB1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jim.2004.03.012_BIB2","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jim.2004.03.012_BIB3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jim.2004.03.012_BIB4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jim.2004.03.012_BIB5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid \u201crafts\u201d","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jim.2004.03.012_BIB6","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/intimm\/10.10.1459","article-title":"Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B cells","volume":"10","author":"Fr\u00e9meaux-Bacchi","year":"1998","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jim.2004.03.012_BIB7","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Gaetno","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2004.03.012_BIB8","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jim.2004.03.012_BIB9","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jim.2004.03.012_BIB10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1046\/j.1365-2141.2002.03935.x","article-title":"Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab","volume":"119","author":"Golay","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jim.2004.03.012_BIB11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunp\u00e4\u00e4","year":"2000","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jim.2004.03.012_BIB12","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell chronic lymphocytic leukemia","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jim.2004.03.012_BIB13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007691-200006000-00010","article-title":"Rituximab (IDEC C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study","volume":"22","author":"Iacona","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jim.2004.03.012_BIB14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2003.50025","article-title":"The mechanisms of action of rituximab in the elimination of tumor cells","volume":"30","author":"Johnson","year":"2003","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jim.2004.03.012_BIB15","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2002-03-0876","article-title":"An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by Rituximab","volume":"101","author":"Kennedy","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jim.2004.03.012_BIB16","first-page":"74","article-title":"Preclinical and phase I and II trials of Rituximab","volume":"26","author":"Maloney","year":"1999","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jim.2004.03.012_BIB17","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-Cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jim.2004.03.012_BIB18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas","volume":"101","author":"Manches","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jim.2004.03.012_BIB19","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jim.2004.03.012_BIB20","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jim.2004.03.012_BIB21","first-page":"253","article-title":"Current status of monoclonal antibody therapy for chronic lymphocytic leukemia","volume":"17","author":"Nabhan","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.jim.2004.03.012_BIB22","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jim.2004.03.012_BIB23","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.4049\/jimmunol.151.3.1702","article-title":"Circulating soluble CR1 (CD35)","volume":"151","author":"Pascual","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2004.03.012_BIB24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jim.2004.03.012_BIB25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-1759(01)00556-7","article-title":"Pharmacokinetics of CAMPATH-1H: assay development and validation","volume":"260","author":"Rebello","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2004.03.012_BIB26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jim.2004.03.012_BIB27","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.4049\/jimmunol.165.10.5954","article-title":"Triggering Fc\u03b1-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy","volume":"165","author":"Stockmeyer","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2004.03.012_BIB28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1008265313133","article-title":"Feasibility and pharmacokinetic study of a chimeric anti-CD 20 monoclonal antibody (IDEC-C2B8, rigguximab) in relapsed B-cell lymphoma","volume":"9","author":"Tobinai","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jim.2004.03.012_BIB29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1191\/0961203303lu449cr","article-title":"Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy","volume":"12","author":"Weide","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.jim.2004.03.012_BIB30","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175904001206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175904001206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T17:07:33Z","timestamp":1682701653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175904001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":30,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0022175904001206"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2004.03.012","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}